The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; 6 of the 28 sources its claims cite were checked for support.
Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone
Open accessAbstract
Succinylacetone (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumarylacetoacetate hydrolase. It is known that patients with this hereditary disease excrete excessive amounts of delta-aminolevulinic acid (ALA) in urine and that certain patients have an accompanying clinical syndrome resembling that of acute intermittent porphyria (AIP). In order to elucidate the relation of succinylacetone to the heme biosynthetic pathway, we have examined the effects of this metabolite on the cellular heme content of cultured avian hepatocytes and on the activity of purified ALA dehydratase from normal human erythrocytes and from mouse and bovine liver. Our data indicate that succinylacetone is an extremely potent competitive inhibitor of ALA dehydratase in human as well as in animal tissues. By using purified preparations of the enzyme from human erythrocytes and mouse and bovine liver, an inhibitor constant ranging from 2 x 10(-7) M to 3 x 10(-7) M was obtained. In cultured hepatocytes, succinylacetone also inhibited ALA dehydratase activity, decreased the cellular content of heme and cytochrome P-450, and greatly potentiated the induction response of ALA synthase to drugs such as phenobarbital, chemicals such as allylisopropylacetamide and 3,5-dicarbethoxy-1,4-dihydrocollidine, and natural steroids such as etiocholanolone. Four patients with hereditary tyrosinemia have been studied and all were found to have greatly depressed levels of erythrocyte ALA dehydratase activity and elevated concentrations of this inhibitor in urine. These findings indicate that tyrosinemia is a disorder of special pharmacogenetic interest because succinylacetone, an abnormal product of the tyrosine metabolic pathway, resulting from the primary gene defect of the disease, profoundly inhibits heme biosynthesis in normal cells through a blockade at the ALA dehydratase level, leading to clinical and metabolic consequences that mimic another genetic disease, AIP.
Overview
CoChat Summary
TL;DR
This paper shows that succinylacetone, a metabolite that accumulates in hereditary tyrosinemia, is a very potent competitive inhibitor of δ-aminolevulinic acid dehydratase (ALA dehydratase), linking the disorder to blocked heme biosynthesis. In cultured chick embryo liver cells it lowers heme and cytochrome P-450 and greatly sensitizes ALA synthase induction, helping explain AIP-like features in some patients.
Key findings
- Succinylacetone competitively inhibited purified ALA dehydratase from human erythrocytes, mouse liver, and bovine liver, with inhibitor constants in the range of 2–3 × 10^-7 M and enzyme Km values of 1.5–2.2 × 10^-4 M, implying about 1,000-fold greater affinity for the enzyme than ALA.
- In cultured chick embryo liver cells, succinylacetone caused dose-dependent inhibition of ALA dehydratase and reduced heme metabolism; at 10^-8 M it decreased cytochrome P-450 by >50%, and total heme fell from 155±8 to 112±3 pmol/mg protein.
- Succinylacetone potentiated ALA synthase induction by porphyrogenic agents by about 3- to 16-fold; with AIA, the lowest detectable induction shifted from >0.5 μg/ml to 0.05 μg/ml (a 10-fold increase in sensitivity).
- In the four hereditary tyrosinemia patients studied, erythrocyte ALA dehydratase activity ranged from 0.4% to 38% of control; in one case it was below the detection limit (<10 nmol PBG/ml RBC·h), and the patient’s urine inhibited normal ALA dehydratase by 28–79%.
Methods
- The study examined four patients with hereditary tyrosinemia, purified ALA dehydratase from human erythrocytes, mouse liver, and bovine liver, and used cultured chick embryo liver cells to test heme metabolism and induction responses.
- ALA dehydratase was purified by chromatography and fractionation methods; inhibition was assayed using purified enzyme preparations and liver-cell homogenates, and heme, cytochrome P-450, heme oxygenase, and ALA synthase were measured in cultured hepatocytes.
- Main analyses included competitive inhibition kinetics (including Dixon plots and Km/Ki comparisons), dose-response assays in cell culture, and rocket immunoelectrophoresis to assess whether patient erythrocytes contained normal amounts of ALA dehydratase protein.
Limitations
- The paper explicitly notes that some findings are “unpublished results” and that one patient’s post-treatment enzyme values were reported as “submitted for publication”, so not all supporting data are fully presented here.
- The text gives only a small clinical sample: four patients with hereditary tyrosinemia, which limits generalization; this is evident from the study design.
- The paper states that several mechanistic points remain speculative, including how succinylacetone blocks ALA binding and the precise basis of the AIP-like neurological symptoms; this is stated in the discussion as unresolved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
6 Valid · 1 Not valid · 12 Not checked · 58 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Succinylacetone (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumarylacetoacetate hydrolase.”
What the sources say
- Partly supportedcites [7] 7. Lindblad, B., S. Lindstedt, and G. Steen. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA. 74: 4641-4645. sourceExperimental — accuracy not yet measured
The Abstract (p. 4641) reports succinylacetone in urine from patients with hereditary tyrosinemia and identifies a possible block at the fumarylacetoacetase step. It says the metabolites “presumably” originate from upstream compounds and suggests that decreased enzyme activity “may be” the primary defect; it does not establish the inherited deficiency as the cause asserted in the claim. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients with this disease excrete excessive amounts of urinary δ-aminolevulinic acid (ALA)¹ (25) and have low ALA dehydratase [EC 4.2.1.24] activity in erythrocytes (6, 7) and in liver (7).”
What the sources say
- Not checked — no full text of the sourcecites [6] 6. Strife, C..F., E. L. Zuroweste, and E. A. Emmett. 1977. Tyrosinemia with acute intermittent porphyria: aminolevulinic acid dehydratase deficiency related to elevated urinary aminolevulinic acid levels. J. Pediatr. 90: 400-404. source
- Supportedcites [7] 7. Lindblad, B., S. Lindstedt, and G. Steen. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA. 74: 4641-4645. source
The Abstract in our indexed copy reports that porphobilinogen synthase (EC 4.2.1.24), the enzyme identified in the citing sentence as ALA dehydratase, had markedly reduced activity in both erythrocytes and liver tissue from patients with hereditary tyrosinemia. No page number is supplied for the passage. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“It has also been established that the levels of this enzyme activity in clinically manifest AIP patients and in clinically latent gene carriers are equally diminished (~50%) from normal (35), indicating that the PBG deaminase defect alone does not determine the induction of hepatic ALA synthase that occurs in clinically manifest AIP (35).”
What the sources say
- Supportedcites [35] 35. Sassa, S., S. Granick, D. R. Bickers, H. L. Bradlow, and A. Kappas. 1974. A microassay for uroporphyrinogen I synthase, one of three abnormal enzyme activities in acute intermittent porphyria, and its application to the study of the genetics of this disease. Proc. Natl. Acad. Sci. USA. 71: 732–736. source
The CONCLUDING COMMENTS of our copy state the point directly: 'It seems unlikely, therefore, that the low URO synthase activity in the liver cells of AIP patients can alone depress hepatic heme synthesis sufficiently to lead to secondary stimulation of ALA synthase production. To elicit the overproduction of this enzyme in individuals carrying the low URO synthase trait, other metabolic factors appear to be required' — URO synthase (EC 4.3.1.8) being the enzyme the field also calls PBG deaminase, as the Abstract and RESULTS AND DISCUSSION make clear. The same section adds that the URO synthase defect 'is clearly not of itself sufficient to determine clinical expression of the AIP trait' and that latent carriers show the same roughly one-half-normal erythrocyte levels as manifest patients (Table 1, Fig. 2), matching the preceding clause of the citing sentence. The source phrases its conclusion with mild hedging ('seems unlikely', 'appear to be required'), but its substantive content is the claim's. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low ALA dehydratase activity is thought to result from enzyme inhibition by accumulation of succinylacetone (4,6-dioxoheptanoic acid) in plasma resulting from the deficiency of 4-fumarylacetoacetate hydrolase [EC 3.7.1.2] in this disease (7).”
What the sources say
- Partly supportedcites [7] 7. Lindblad, B., S. Lindstedt, and G. Steen. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA. 74: 4641-4645. sourceExperimental — accuracy not yet measured
The passage labeled Abstract reports very low porphobilinogen synthase (ALA dehydratase) activity in hereditary tyrosinemia, identifies succinylacetone as an inhibitor in patients’ urine, and suggests a block at the fumarylacetoacetase step. It does not establish the claim’s specific location of succinylacetone accumulation in plasma. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The activity of the enzyme ranged from 0.4 to 38% of control incubations with normal erythrocytes (RBC).”
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 77 claims and to verify the 2 references still open.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SA accumulation is thus the indirect result of the complete or incomplete block of the FAH enzyme, and SA accumulation has been linked to certain pathological aspects of the disorder (1, 2, 37, 38).”
From Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1 (2001) · cites this paper as [37]
Experimental — accuracy not yet measured
Citations
Cites
Weber, K., & Osborn, M. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94333-4 · Cited by 20,298
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
Laurell, C.-B. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90246-6 · Cited by 4,401
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · cited 2×
“(7) first reported that the high urinary excretion of ALA in patients with hereditary tyrosinemia is due to inhibition of ALA dehydratase by succinylacetone and their studies indicated that the primary enzymatic defect in hereditary tyrosinemia might be a decreased activity of fumarylacetoacetate hydrolase, an enzyme…”
Backgroundδ-Aminolevulinic Acid Synthetase
Marver, H. S., Collins, A., Tschudy, D. P., & Rechcigl, M. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99725-5 · Cited by 290
Maines, M., & Kappas, A. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41402-6 · Cited by 224
Self-citationδ-Aminolevulinic Acid Dehydratase of Rhodopseudomonas spheroides
Nandi, D. L., & Shemin, D. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)56978-2 · Cited by 213
Immunochemical Studies on Electron Transport Chains Involving Cytochrome P-450
Masters, B. S. S., Baron, J., Taylor, W. E., Isaacson, E. L., & LoSpalluto, J. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)62065-4 · Cited by 211
Purification and properties of delta-aminolevulinate dehydrase from human erythrocytes.
Anderson, P. M., & Desnick, R. J. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50263-5 · Cited by 175
Granick, J. L., Sassa, S., Granick, S., Levere, R. D., & Kappas, A. (1973) · Biochemical Medicine · doi:10.1016/0006-2944(73)90018-5 · Cited by 173
Self-citationSassa, S., & Kappas, A. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40571-0 · Cited by 159
Self-citation
Research works printed but not linked: 2
- [1]1. LaDu, B. N., and L. R. Gjessing. 1978. Tyrosinosis and tyrosinemia. In The Metabolic Basis of Inherited Disease. J. B. Stanbury, J. B. Wyngaarden, and D. S. Frederickson, editors. McGraw-Hill, New York. 4th edition. 256-267.
- [38]38. Kappas, A., S. Sassa, and K. E. Anderson. 1982. The porphyrias. In The Metabolic Basis of Inherited Disease. j. B. Śtanbury, J. B. Wyngaarden, D. S. Frederickson, J. S. Goldstein, and M. S. Brown, editors. McGraw-Hill, New York, 5th edition. 1301-1384.
Cited by
Puy, H., Gouya, L., & Deybach, J.-C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61925-5 · Cited by 729
Rev-erbα, a Heme Sensor That Coordinates Metabolic and Circadian Pathways
Yin, L., Wu, N., Curtin, J. C., Qatanani, M., Szwergold, N. R., Reid, R. A., Waitt, G. M., Parks, D. J., Pearce, K. H., Wisely, G. B., et al. (2007) · Science · doi:10.1126/science.1150179 · Cited by 707
Biosynthesis of heme in mammals
Ajioka, R. S., Phillips, J. D., & Kushner, J. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.005 · Cited by 493
Grompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 232
Metadata
- Authors
- Sassa, S., & Kappas, A.
- Affiliations
- Rockefeller University Hospital (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1983-03-01
- Volume
- 71
- Issue
- 3
- Pages
- 625-634
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC436912
- OpenAlex
- W2081959583
- Semantic Scholar
- 4ac7d88a5c653026d8460d83904e6a95c71936e1
- Cited by
- 145
- References
- 39
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 4 · 2017: 5 · 2016: 8 · 2015: 3 · 2014: 4 · 2013: 2 · 2012: 3
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Keywords
- hereditary tyrosinemia, succinylacetone, delta-aminolevulinic acid dehydratase, heme biosynthesis, fumarylacetoacetate hydrolase deficiency, acute intermittent porphyria, competitive inhibition, cytochrome P450, hepatocytes, erythrocytes, pharmacogenetics, urinary metabolites
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Porphobilinogen Synthase, Animals, Cattle, Chick Embryo, Erythrocytes, Heme, Heptanoates, Heptanoic Acids, Humans, Liver, Mice, Inbred BALB C, Species Specificity, Tyrosine, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone. https://app.cochat.ai/papers/10.1172/jci110809
- The paper
- Sassa, S., & Kappas, A. (1983). Hereditary Tyrosinemia and the Heme Biosynthetic Pathway: Profound Inhibition of δ-Aminolevulinic Acid Dehydratase Activity by Succinylacetone. Journal of Clinical Investigation. https://doi.org/10.1172/jci110809
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.